Vera Therapeutics (VERA) Income towards Parent Company (2020 - 2026)

Vera Therapeutics has reported Income towards Parent Company for 7 years, with the latest figure at -$120.6 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 131.57% year-over-year to -$120.6 million; the trailing twelve-month figure through Mar 2026 stood at -$367.0 million (down 771.63% YoY), and the FY2025 full-year result was -$1000.0, up 100.0% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$120.6 million, down from -$90.6 million in the prior quarter.
• The five-year high for Income towards Parent Company was $91.1 million in Q4 2024, with the low at -$120.6 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$27.8 million across 5 years, with a median of -$28.8 million in 2024.
• The largest YoY upside for Income towards Parent Company was 334.44% in 2022 against a maximum downside of 263.03% in 2022.
• Vera Therapeutics' Income towards Parent Company stood at $38.9 million in 2022, then jumped by 43.21% to $55.7 million in 2023, then surged by 63.46% to $91.1 million in 2024, then slumped by 199.45% to -$90.6 million in 2025, then slumped by 33.12% to -$120.6 million in 2026.
• The last three Income towards Parent Company figures came in at -$120.6 million (Q1 2026), -$90.6 million (Q4 2025), and -$80.2 million (Q3 2025), per Business Quant data.